Food and Drug Administration (FDA) is requiring changes to the prescribing labels for tranexamic acid injections after receiving medication error reports of the acid administered intrathecally or as an epidural injection. Tranexamic acid injection is intended for short-term use to reduce or prevent hemorrhage in patients with hemophilia and should only be administered intravenously. The changes to prescribing labels include a boxed warning that informs about the risks of neuraxial administration of the tranexamic acid injection, a statement that it should not be administered neuraxially, and an update to the dosage and administration section outlining instructions for preparing and delivering the diluted solution.